- Home
- TRBG vs COYA Comparison
TRBG vs COYA Comparison
Compare TRBG & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRBG | COYA |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | Israel | United States |
| Employees | 20 | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.2M | 102.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TRBG | COYA |
|---|---|---|
| Price | $3.87 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.21 |
| AVG Volume (30 Days) | 64.7K | ★ 130.8K |
| Earning Date | 09-24-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $387.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $3.50 | $3.71 |
| 52 Week High | $5.84 | $7.75 |
Technical Indicators
Market Signals| Indicator | TRBG | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 30.38 | 54.67 |
| Support Level | $3.50 | $4.42 |
| Resistance Level | $4.09 | $5.17 |
| Average True Range (ATR) | 0.34 | 0.26 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.09 | 65.69 |
Price Performance
Historical ComparisonAbout TRBG TurboGen Ltd. Ordinary Shares
Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.